FDA Approves Fluarix for Pediatric Use
FDA Approves Seasonal Influenza Vaccine Fluarix for Pediatric Use
SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved use of the seasonal influenza vaccine Fluarix for children ages 3 years to 17 years. Previously, this vaccine, which contains inactivated (killed) influenza A and B viruses, had been approved for use in adults, ages 18 years and older.
The safety and effectiveness of Fluarix for use in children ages 3 years and older is documented by a U.S. study comparing 2,115 children who received Fluarix with 1,210 children who received Fluzone, a different influenza vaccine already licensed by the FDA for use in children ages 6 months and older. Study results showed that children 3 years and older vaccinated with Fluarix and Fluzone produced similar amounts of antibodies in the blood at levels considered likely to be protective against seasonal influenza.
Fluarix is a seasonal influenza vaccine not intended to protect against the
2009 H1N1 influenza virus.
"This approval of an additional seasonal influenza vaccine for children provides help in protecting them against influenza," said Karen Midthun, M.D., acting director of the FDA's Center for Biologics Evaluation and Research. "Children are very vulnerable to the influenza virus and are more likely to be hospitalized for associated problems."
With today's approval, there are now four companies approved by the FDA to manufacture seasonal influenza vaccine for use in children.
Influenza is far more dangerous than the common cold for children, who often require medical care, especially if they are younger than 5 years. It is best to vaccinate children each fall, but vaccination also can occur in the winter months when influenza season often peaks.
Common adverse events experienced after administration of Fluarix are typical of those for flu shots and include pain, redness, and swelling at the injection site as well as irritability, loss of appetite, and drowsiness.
Because Fluarix contains a small amount of egg protein, it should not be administered to anyone allergic to eggs or egg products.
Fluarix is manufactured by GlaxoSmithKline Biologicals of Dresden, Germany.
For more information:
FDA Web site on Influenza Virus Vaccine Safety and Availability http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/VaccineSafety/ucm110288.htm
Media Inquiries: Peper Long, 301-796-4671, email@example.com Consumer Inquiries: 888-INFO-FDA
SOURCE U.S. Food and Drug Administration
Posted: October 2009
- GSK Receives FDA Approval for Expanded Indication for Fluarix Quadrivalent (Influenza Vaccine) for Persons 6 Months and Older - January 11, 2018
- FDA Approves GlaxoSmithKline's Fluarix Quadrivalent - Four-strain Seasonal Influenza Vaccine for Use in the U.S. - December 17, 2012
- Fluarix GlaxoSmithKline - Treatment for Influenza Vaccination - August 31, 2005
- GlaxoSmithKline Submits Biologics License Application for FDA Approval of Fluarix - May 25, 2005